马来酸桂哌齐特联合丹参川芎嗪注射液治疗脑梗死的疗效

 目的 通过观察治疗前后患者血清中白介素-18、可溶性细胞间黏附分子-1、胰岛素样生长因子-1的变化,探讨马来酸桂哌齐特(克林澳)联合丹参川芎嗪注射液治疗脑梗死患者的疗效。方法 选择2015-09至2018-12在医院诊治的脑梗死患者135例,根据治疗方法不同分为对照组(n=65)与联合组(n=70)。对照组给予克林澳治疗,联合组在对照组治疗的基础上联合丹参川芎嗪注射液治疗,两组均治疗观察3个月,记录与检测患者血清IL-18、sICAM-1、IGF-1的变化。结果 所有患者均顺利完成治疗,治疗期间无严重不良反应发生。联合组的总有效率97.1%,高于对照组的86.2%(P＜0.05)。两组治疗后的MoCA评分、颅脑椎动脉与基底动脉血流速度都高于治疗前,联合组评分为(27.38±1.49)分,高于对照组的(22.88±2.69)分。两组治疗后的血清IL-18、sICAM-1、IGF-1水平均低于治疗前,联合组也低于对照组(P＜0.05)。结论 克林澳联合丹参川芎嗪注射液治疗脑梗死能抑制血清IL-18、sICAM-1、IGF-1的表达,改善脑血流状况,提高患者的认知功能与总体治疗效果。

Changes of serum IL-18, sICAM-1 and IGF-1 in patients with cerebral infarction treated with Cinepazide Maleate and Danshen Ligustrazine injection

ObjectiveTo investigate the therapeutic effect of Cinepazide Maleate combined with Danshen Ligustrazine injection against cerebral infarction by observing changes in serum interleukin (IL)-18, soluble intercellular adhesion molecule (sICAM)-1, and insulin-like growth(IGF)-1 in patients.Methods One hundred and thirty-five cases of patients with cerebral infarction who were treated in our hospital between September 2015 and December 2018 were selected and divided into the control group(n=65) and the combination group(n=70) according to treatment methods. The control group was treated with Cinepazide Maleate, while the combination group was additionally treated with Danshen Ligustrazine injection. Both groups were treated for 3 months, and the levels of serum IL-18, sICAM-1 and IGF-1 were detected and recorded.Results All the patients completed the treatment and no serious adverse reactions occurred during the treatment. The total effective rate of the combination group was 97.1%, which was significantly higher than that of the control group (86.2%) (P<0.05). The MoCA scores, cranial vertebral artery and basilar artery blood flow velocity in the two groups were significantly higher after treatment (P<0.05), especially in the combination group (P<0.05). The levels of serum IL-18, sICAM-1 and IGF-1 in the two groups were significantly lower after treatment (P<0.05), particularly in the combination group (P<0.05).Conclusions Cinepazide Maleate combined with Danshen Ligustrazine injection, when used in the treatment of cerebral infarction, can inhibit the expressions of serum IL-18, sICAM-1 and IGF-1, boost the cerebral blood flow and improve the cognitive function and overall therapeutic effect.